KIMMTRAK achieved $310 million in net sales for 2024, with $84.1 million in Q4, marking 11 consecutive quarters of growth and launches in 14 new territories.
Immunocore has dosed the first patient in a Phase 1 trial of IMC-P115C, a half-life extended ImmTAC candidate targeting PRAME, designed to improve patient convenience through less frequent administration.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.